Next Article in Journal
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma
Previous Article in Journal
Non-Immunotherapy Options for the First-Line Management of Hepatocellular Carcinoma: Exploring the Evolving Role of Sorafenib and Lenvatinib in Advanced Disease
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Review

Management of Hepatocellular Carcinoma after Progression on First-Line Systemic Treatment: Defining the Optimal Sequencing Strategy in Second Line and Beyond

Tom Baker Cancer Centre, University of Calgary, Calgary, AB T2N 4N2, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(s3), 173-180; https://doi.org/10.3747/co.27.7103
Received: 5 August 2020 / Revised: 6 September 2020 / Accepted: 7 October 2020 / Published: 1 November 2020
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. It has a high mortality rate, especially when localized treatments fail. For about a decade, the only systemic treatment shown to improve survival was sorafenib. Recently, lenvatinib was found to be noninferior to sorafenib for overall survival, and combination atezolizumab–bevacizumab improved survival compared with sorafenib. Similarly, in the post-sorafenib setting, a number of recent positive clinical trials have been reported, and they indicate that regorafenib, cabozantinib, and ramucirumab are effective and safe in the second-line setting. With so many new options available, including immunotherapy, it is challenging to define the best sequence of systemic treatment for patients with hcc. In the present review, we introduce the current data for second-line systemic treatment and beyond in HCC. A treatment algorithm is also suggested, based on the best available evidence and expert opinion.
Keywords: hepatocellular carcinoma; treatment sequencing; second-line management; third-line management hepatocellular carcinoma; treatment sequencing; second-line management; third-line management
MDPI and ACS Style

Amaro, C.P.; Tam, V.C. Management of Hepatocellular Carcinoma after Progression on First-Line Systemic Treatment: Defining the Optimal Sequencing Strategy in Second Line and Beyond. Curr. Oncol. 2020, 27, 173-180. https://doi.org/10.3747/co.27.7103

AMA Style

Amaro CP, Tam VC. Management of Hepatocellular Carcinoma after Progression on First-Line Systemic Treatment: Defining the Optimal Sequencing Strategy in Second Line and Beyond. Current Oncology. 2020; 27(s3):173-180. https://doi.org/10.3747/co.27.7103

Chicago/Turabian Style

Amaro, C. P., and V. C. Tam. 2020. "Management of Hepatocellular Carcinoma after Progression on First-Line Systemic Treatment: Defining the Optimal Sequencing Strategy in Second Line and Beyond" Current Oncology 27, no. s3: 173-180. https://doi.org/10.3747/co.27.7103

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop